<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640051</url>
  </required_header>
  <id_info>
    <org_study_id>version 1.0 26/10/2020</org_study_id>
    <nct_id>NCT04640051</nct_id>
  </id_info>
  <brief_title>Preprocedural Assessment of Anatomy and Device Sizing With CT and 3D Simulation in Left Atrial Appendage Occlusion.</brief_title>
  <acronym>PRECISE LAAO</acronym>
  <official_title>Preprocedural Assessment of Anatomy and Device Sizing With CT and 3D Simulation in Left Atrial Appendage Occlusion: the PRECISE LAAO Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the current proposal are to analyse to what extend:&#xD;
&#xD;
        1. The use of 3D in silico simulation by FEops HEARTguide improves of influences the&#xD;
           pre-procedural assessment and device size selection and to what extend it correlates&#xD;
           with final implanted device size and depth compared to TEE, CT and angiography.&#xD;
&#xD;
        2. The use of 3D in silico simulation by FEops HEARTguide increases the operator's&#xD;
           confidence in the device size selection.&#xD;
&#xD;
      A total of 100 consecutive patients for the total registry, or 15 to 20 consecutive patients&#xD;
      per center, with standard of care follow-up at ±6 weeks and 1 year post procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Left atrial appendage (LAA) occlusion (LAAO) is a well-accepted alternative to oral&#xD;
      anticoagulant in the prevention of stroke or systemic thromboembolism in patients with atrial&#xD;
      fibrillation (AF).1 While the occlusion is effective, the procedure can sometime be&#xD;
      challenging. Part of the challenge is based on the high degree of variability, both at the&#xD;
      patient level (anatomy, size, access, filling status etc); and at the device level (different&#xD;
      architecture, size, depth, degree of conformity or compression of the device etc.). This is&#xD;
      reflected in the percentage change in device sizes of 6.1% to 6.4%; inability to close the&#xD;
      LAA 1% to 2.7%; complications such as embolization, tamponade etc.; residual leaks and&#xD;
      chances for thrombus formation and subsequent stroke or systemic embolization; lengthy&#xD;
      procedures etc.2,3 A well-prepared preprocedural planning addressing the exact anatomy of the&#xD;
      left atrial appendage in conjunction with the optimal device size and conformability, results&#xD;
      in optimal device selection, reduced instrumentation in the left atrium, faster and safer&#xD;
      procedure and optimal final occlusion of the LAA. Different and complimentary techniques are&#xD;
      being used by implanting teams, such as transoesophageal echocardiography (TEE), computed&#xD;
      tomography (CT) scan, angiography, 3D reconstruction and 3D printing etc.&#xD;
&#xD;
      Some centres are using FEops HEARTguideTM as part of their preprocedural assessment. This is&#xD;
      a computational tomography (CT)-based 3D in silico simulation technology suite relying on&#xD;
      proprietary computational modelling and simulation techniques, offering physicians detailed&#xD;
      preoperative insights into the interaction between transcatheter structural heart devices and&#xD;
      the patient's anatomy. It is CE-marked and commercially available on the European and&#xD;
      Canadian market. It is currently being used in 81 hospitals in 22 countries.&#xD;
&#xD;
      Belgian Hospitals who are using 3D simulations by FEops HEARTguide as part of their&#xD;
      preprocedural assessment are asked to participate to this prospective multicentric registry.&#xD;
      The present registry aims to compare all preprocedural imaging tools and to investigate to&#xD;
      what extend 3D in silico simulations influences device size selection in LAAO.&#xD;
&#xD;
      The objectives of the current proposal are to analyse to what extend:&#xD;
&#xD;
        1. The use of 3D in silico simulation by FEops HEARTguide improves of influences the&#xD;
           pre-procedural assessment and device size selection and to what extend it correlates&#xD;
           with final implanted device size and depth compared to TEE, CT and angiography.&#xD;
&#xD;
        2. The use of 3D in silico simulation by FEops HEARTguide increases the operator's&#xD;
           confidence in the device size selection.&#xD;
&#xD;
      A total of 100 consecutive patients for the total registry, or 15 to 20 consecutive patients&#xD;
      per center, with standard of care follow-up at ±6 weeks and 1 year post procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Improvement in pre-procedural device size selection by use of FEops HEARTguide</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Correlation between device size selection by use of FEops HEARTguide and implanted device size</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>LAAO With Amplatzer Amulet</condition>
  <arm_group>
    <arm_group_label>LAAO group</arm_group_label>
    <description>Patients scheduled for LAAO with Amplatzer Amulet (Abbott) and for whom a 3D in silico simulation by FEops HEARTguide is available and reviewed before implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LAAO</intervention_name>
    <description>LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection</description>
    <arm_group_label>LAAO group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 100 consecutive patients, schedule for LAAO with Amplatzer Amulet (Abbott) will&#xD;
        be enrolled in this prospective registry after receiving signed informed consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient signed informed consent&#xD;
&#xD;
          -  Patient scheduled for LAAO with Amplatzer Amulet (Abbott)&#xD;
&#xD;
          -  3D in silico simulation by FEops HEARTguide available and reviewed before implantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - 3D in silico simulation by FEops HEARTguide not available or not reviewed before&#xD;
        implantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Buysschaert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Jan AV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ian Buysschaert, MD, PhD</last_name>
    <phone>003250452670</phone>
    <email>ian.buysschaert@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Lycke, MSc, PhD</last_name>
    <phone>003250453293</phone>
    <email>michelle.lycke@azsintjan.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mi.stusec-cardiologie@zna.be</email>
    </contact>
    <investigator>
      <last_name>Paul Vermeersch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Buysschaert, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Vandenbussche</last_name>
      <email>karen.vandenbussche@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Stijn Lochy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Swijsen</last_name>
      <email>Caroline.Swijsen@zol.be</email>
    </contact>
    <investigator>
      <last_name>Maximo A Rivero, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>kristoff.cornelis@azmmsj.be</email>
    </contact>
    <investigator>
      <last_name>Kristoff Cornelis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sart Tilman - CHU de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mathieu.lempereur@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Mathieu Lempereur, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Ian Buysschaert</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

